TRIMTECH Therapeutics, a biotech firm creating novel, small molecule therapeutics that selectively degrade protein aggregates, to fight neurodegenerative ailments, right this moment introduced the appointment of Dr Mike Hutton to its Scientific Advisory Board (SAB). Mike will present professional steering to help the event of the Firm’s focused protein degradation (TPD) TRIMTAC™ and TRIMGLUE™ pipeline, together with for Alzheimer’s and Parkinson’s illness targets.
Mike has over 30 years’ expertise in neurodegenerative illness analysis and drug improvement, together with in his earlier roles as CSO and Vice President of Neurodegeneration Analysis and UK Web site Scientific Chief at Eli Lilly and Firm, the place he led on drug discovery for Alzheimer’s Illness, Parkinson’s Illness and fronto-temporal dementia. He has additionally held a Senior Director position at MSD and was Guide and Professor of Neuroscience on the Mayo Clinic. While on the Mayo Clinic, Mike’s crew was instrumental in figuring out the genetic causes of fronto-temporal dementia, together with mutations in tau and progranulin. His work on tau led to him receiving the Potamkin and MetLife prizes. Mike holds a BSc in Biochemistry from the College of Manchester and a PhD in Neuroscience from the College of Cambridge.
We’re delighted to welcome Mike as the most recent member of our not too long ago fashioned Scientific Advisory Board. His in depth experience in neurodegenerative illness therapeutics shall be an excellent asset as we proceed to advance our mission to ship first-in-class medicines to deal with the important want for cost-effective, disease-modifying remedies for neurodegeneration that may attain broad affected person populations.”
Dr Nicola Thompson, CEO, TRIMTECH Therapeutics
Dr Mike Hutton, Scientific Advisor for TRIMTECH Therapeutics, added: “TRIMTECH’s novel strategy is main the best way within the improvement of small molecule CNS penetrant degraders for neurological issues, addressing the tough to drug targets underpinning these ailments. I’m delighted to hitch the SAB – the Firm has assembled a superb crew, and I stay up for serving to information the event of those much-needed, accessible therapeutic choices.”
